Cartesian Therapeutics(US:RNAC)2020-09-18 17:41SEL-212 Program for Chronic Refractory Gout - SEL-212 targets a $1 billion+ chronic refractory gout market with high unmet need[6,19] - Phase 2 study showed 66% of evaluable patients achieved Serum Uric Acid (SUA) level <6 mg/dL after 20 weeks of monthly SEL-212 treatment[21,22] - COMPARE trial is ongoing to evaluate SEL-212 vs pegloticase, with top-line data expected in Q3 2020[6,38,39] - Phase 3 pivotal program against placebo is expected to commence in Q3 2020[6,40] - Selecta entered a global licensing agreement with Sobi (excluding China) for SEL-212, receiving $100 million in initial payments and up to $630 million in milestones and tiered double-digit royalties[6,44] ImmTOR Platform and Gene Therapy - ImmTOR platform aims to unlock the full potential of biologic therapies by mitigating Neutralizing Antibody (Nab) formation[5,71] - Preclinical data suggests ImmTOR-powered AAV8 gene therapy can be re-dosed without NAb formation or loss of therapy expression[56,57] - MMA program is expected to enter clinic in 1H 2021 with preliminary POC data in 2H 2021[5,62] Strategic Collaborations and Financial Position - Selecta has a 50/50 collaboration agreement with AskBio[5,62] - Selecta has license agreements with AskBio for Pompe disease, Sarepta for DMD and certain LGMD subtypes, and Spark for Hemophilia A[5,62,65] - The company is well-capitalized with funding into the first quarter of 2023, pro forma for the Sobi agreement[70]